When should bilevel positive airway pressure (BiPAP) be initiated in a patient with acute or worsening respiratory failure?

When to Start BiPAP

BiPAP should be initiated when pH ≤7.35, PaCO₂ >45 mmHg, and respiratory rate >20-24 breaths/min despite standard medical therapy in patients with acute hypercapnic respiratory failure, particularly COPD exacerbations. 1

Clinical Criteria for BiPAP Initiation

For Acute Hypercapnic Respiratory Failure (COPD)

The most definitive criteria come from the ERS/ATS 2017 guidelines 1:

• pH ≤7.35
• PaCO₂ >45 mmHg
• Respiratory rate >20-24 breaths/min
• Despite optimal standard medical therapy

There is no lower pH limit below which BiPAP is contraindicated - even severe acidosis warrants a trial, though failure risk increases with lower pH and requires very close monitoring with immediate access to intubation 1. The BTS/ICS guidelines confirm these same criteria should be applied across hypercapnic conditions including obesity hypoventilation syndrome 2.

For Cardiogenic Pulmonary Edema

Either BiPAP or CPAP should be initiated for acute respiratory failure due to cardiogenic pulmonary edema 1. The evidence shows:

• Reduces intubation rates (RR 0.60)
• Decreases hospital mortality (RR 0.80)
• No difference in efficacy between BiPAP and CPAP

Research supports early application - within one hour of presentation - significantly reduces emergency department length of stay in pulmonary edema patients (85% discharged within 4 hours with early BiPAP vs 15% with delayed application, p=0.001) 3.

Important caveat: This recommendation does not apply to patients with acute coronary syndrome or cardiogenic shock, as these populations were excluded from trials 1.

For Post-Extubation Support

BiPAP should be considered prophylactically for high-risk patients following extubation 2. The 2026 ATS guideline provides a risk-stratified approach 4:

• Low-risk patients: HFNC acceptable
• High-risk patients: NIV/BiPAP preferred to reduce reintubation

Risk factors include underlying COPD, hypercapnia, poor cough effectiveness, and high sputum load 2.

For Preoxygenation Before Intubation

Strong recommendation for BiPAP or HFNC during preoxygenation prior to endotracheal intubation to prevent peri-intubation hypoxemia 4.

Timing and Trial Assessment

A 30-minute trial determines success or failure 5. Post-trial arterial blood gas at 30 minutes predicts outcome:

• Success: pH improves to ≥7.34, PaCO₂ decreases
• Failure: pH remains ≤7.27, PaCO₂unchanged or worsening (p<0.002)

Pretrial values do not predict success, supporting trials for all stable patients with acute respiratory failure 5. If no improvement within 30 minutes, proceed to intubation.

Special Populations

Neuromuscular Disease/Myasthenic Crisis

BiPAP may prevent intubation if **PaCO₂ <50 mmHg at onset** - hypercapnia >50 mmHg predicts BiPAP failure and need for intubation 6.

Obesity Hypoventilation Syndrome

• Requires high pressures (IPAP >30, EPAP >8)
• Address fluid overload aggressively
• Consider HDU/ICU placement due to higher failure risk and difficult intubation 2

Common Pitfalls

1. Delaying BiPAP initiation: Early application (within 1 hour) improves outcomes 3
2. Continuing failed trials beyond 30 minutes: Lack of ABG improvement at 30 minutes mandates intubation 5
3. Using BiPAP for unexpected post-extubation failure: Should NOT be used routinely in this scenario 2
4. Ignoring contraindications: Cardiogenic shock and acute coronary syndrome requiring revascularization are relative contraindications 1

The evidence consistently demonstrates that BiPAP reduces intubation rates, decreases mortality in appropriate populations, and shortens hospital stays when initiated according to these specific physiologic criteria with close monitoring for treatment failure 1, 2, 4.